

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORLED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIGURE 1


1 2 3 4 5 6 7 8



β -actin

FOIA b 7 - D

FIGURE 2



IL-10----

FIGURE 3




FIGURE 4




FIGURE 5A

1 2 3 4 5




FIGURE 5B

1 2 3 4 5




FIGURE 6





FIGURE 7

| | | | |
|----------------------------|--|-----|--|
| Leader ----- | | | |
| RAT | ATGGGCAGTCCGGTATTTCAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG | 67 | |
| MOU | -----T-----C-----A-T---G----- | 67 | |
| HUM | --GA-----TG---C---CT-----T-----G-T---T---G- | 55 | |
| V-like domain ----- | | | |
| RAT | CAGCAGTAGCGCTGAGCACAGCTCAAGTGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC | 134 | |
| MOU | -----GC----- | 134 | |
| HUM | -----G-T---T-----A-----C-----A---T--- | 122 | |
| RAT | AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCCTTGATTGTGACATGGCAGAAAAAG | 201 | |
| MOU | -----A-----T----- | 201 | |
| HUM | -----T-----AAA-C-----GC---ATG-----G---C-C----- | 189 | |
| RAT | AAAGCCGTAGGCCCCAGAAAACATGGTCACTTACAGCAAAGCCCATGGGGTTGTCATTACAGCCACCT | 268 | |
| MOU | -----GA-----C-----A-----A---C---TG--- | 268 | |
| HUM | -----T---A-----C-T---G-GAA-----G---G---C---TG--- | 256 | |
| RAT | ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC | 335 | |
| MOU | -----TG---A-----G---T-----CA | 335 | |
| HUM | -T---G---A-----T---CC-----C-A---T---C-----T-TC-- | 323 | |
| RAT | CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA | 402 | |
| MOU | -A-T-GA---GA---C-----C-----T---CA-----A---A--- | 402 | |
| HUM | -----G-----A---G---T-----T-CC-----T-T-----A---A---G | 390 | |
| C-like domain ----- | | | |
| RAT | GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTTGAAGACCACCTAA | 469 | |
| MOU | -----C----- | 469 | |
| HUM | --C-----C---CG-----TC-----A-TC-C----- | 457 | |
| RAT | ACATCACGTGCTCTGCAACTGCCCCGCCAGCCCCTGCCATCTCCTGGAAGGGCACTGGGTGAGGAAT | 536 | |
| MOU | -----T-----G-----T-----A-----T-----A----- | 536 | |
| HUM | -T-----T-----C-----CATGG---T-----T-C-C----- | 524 | |
| RAT | TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCACCAGCATCCTCCGGGTC | 603 | |
| MOU | -----C-----T----- | 603 | |
| HUM | ---A-----A-T---C---TG---T---CC-----C---G---T-----ATA-- | 591 | |
| RAT | AAAGACCCCAAACTCAGGTTGGAAAGGAAGTGATCTGCCAGGTTTATACTTGGGGAATGTGATTG | 670 | |
| MOU | ----- | 670 | |
| HUM | -----T---G-A-----G---G-----GC-GC---C-----C---CC- | 658 | |
| Transmembrane region ----- | | | |
| RAT | ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCACTGCTGCTGAGCATTGTTTCTCT | 737 | |
| MOU | -----T-----T-----A----- | 737 | |
| HUM | ---TT-----A-CCG-CA-----C-A-----T---G---AT---A-----C--- | 725 | |
| Cytoplasmic region ----- | | | |
| RAT | GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCAGAAATCAGGAGCGGGGT | 804 | |
| MOU | -----A-----C-----T----- | 804 | |
| HUM | -----C---C-A---A---C-G-----T---G-----C---A--- | 792 | |
| RAT | GAGTCATCACAGGGGATGCAAAGAATGAAATAA | 837 | |
| MOU | ---A----- | 837 | |
| HUM | ----TG-----AG-T---A-----C---- | 825 | |

[illegible]

* invariant cysteine residues; ** invariant asparagine (N-linked oligosaccharides)

FIGURE 9



CELLS added to C57BL/6 RESPONDER SPLEEN CELLS

FIGURE 10





FIGURE 11



NPC from Flt3 treated mice

FIGURE 12





FIGURE 14



NPC cells infused into renal transplant recipients

FIGURE 15




FIGURE 16





FIGURE 17

Monoclonal antibodies added to culture

FIGURE 18A





FIGURE 18B



00047278.073004
FO0270" 8224T660

Survival post EL4 or C1498 tumor inoculation in C57BL/6 bone marrow transplant recipients





FIGURE 19




FIGURE 20

Role of CD4⁺/CD8⁺ cells in tumor immunity in bone marrow transplant recipients




FIGURE 21

CD200Fc reverses tumor protection in C3H recipients of C57BL/6 bone marrow




FIGURE 22

CD200Fc reverses protection from early mortality in C57BL/6 mice immunized with CD80-transfected EL4 cells




FIGURE 23

Anti-CD200 reveals protection in mice preimmunized with CD86-tumor cells






FIGURE 24

**Relative CD200 mRNA expression in spleen following
immunization with EL4-CD86 vs EL4-CD80**



Cells used for immunization of C57BL/6

FIGURE 25

CD200:CD200^{r+} interactions block tumor immunity in BL/6 marrow recipients





FIGURE 26

CD200Fc interacts with anti-CD4/CD8 to block tumor immunity

a)



b)




FIGURE 27

CD200Fc reverses protection from early mortality in anti-CD4 treated C57BL/6 mice immunized with CD80-transfected EL4 cells





FIGURE 28


FIGURE 29A and B



A

B


FIGURE 30A and B



A

B

FIGURE 31A and B



B

A